The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Iovance Biotherapeutics (Silver).
The Skin Cancer Channel is supported with funding from Iovance Biotherapeutics (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BTOG 2021 | Cellular therapy in solid tumors
Andrew Furness, BSc (Hons) MBBS, MRCP, PhD, The Royal Marsden NHS Foundation Trust, London, UK, discusses the use of cellular therapies in the treatment of solid tumors, in particular commenting on the use of tumor infiltrating lymphocytes (TILs). Dr Furness reports on recent trials of TILs for the treatment of relapsed/refractory melanoma, non-small cell lung cancer and head and neck cancer. Dr Furness also talks on the use of T-cell receptors (TCRs) and chimeric antigen receptor T-cell (CAR-T) therapies for the treatment of solid tumors. This interview took place during the 19th British Thoracic Oncology Group (BTOG) Annual Conference 2021.
